Vaccine (Recombinant protein vaccine) · Immune activation, directed at SARS-CoV-2 spike protein · developed by Novavax
SARS-CoV-2 rS vaccine is a recombinant spike protein vaccine administered intramuscularly to induce immune responses against SARS-CoV-2. It is studied in COVID-19 and influenza.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05519839 | Phase 2 | COVID-19 | Completed | NVAX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
COVID-19Influenza
Updated Oct 3, 2026. Something wrong or missing? Report it on the NVAX page.
See NVAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVAX catalysts and pipeline →